Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAST is an investigational, standardized **Centella asiatica** botanical extract developed by Oregon Health & Science University for diabetic neuropathy. It contains selected pentacyclic triterpenes, principally asiaticoside, madecassic acid, and asiatic acid. Rather than having a defined single molecular target, its proposed activity is neurotrophic and microcirculatory support in peripheral nerves, with potential disease-modifying effects on diabetic neuropathy. In a 52-week randomized, double-blind, placebo-controlled Phase 2 pilot study in people with type 2 diabetes and symptomatic symmetrical distal neuropathy, CAST was associated with reductions in total neuropathic symptom score and paresthesia. ([minervamedica.it](https://www.minervamedica.it/en/journals/esperienze-dermatologiche/article.php?cod=R50Y2018S01A0012))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAST.